Curr Drug Metab. 2002 Feb;3(1):73-95.

Combinations against combinations: associations of anti-HIV 1 reverse transcriptase drugs challenged by constellations of drug resistance mutations.

Source

Istituto di Genetica Biochimica ed Evoluzionistica IGBE-CNR, Pavia, Italy. maga@igbe.pv.cnr.it

Abstract

The reverse transcriptase inhibitors still represent the majority of the clinically used anti-HIV drugs and constitute the main backbone of currently employed combinatorial regimens. A major obstacle to successfull chemotherapic eradication of HIV is the emergence of viral strains resistant to the drugs in use. Counteracting the emergence of resistance necessitates alternating the panel of agents employed. In order to rationally design alternative drug combinations, physicians not only must know the genotype of the emerging viral strains, but should also be able to correlate it with its resistant phenotype. However, resistant viral strains usually carry multiple mutations, whose reciprocal influences on the overall level of resistance are largely unknown. Moreover, the choice of agents to be combined must take in account drug-drug interactions and adverse metabolic effects. This review will outline the main pharmacological and clinical features of the currently utilised anti-reverse transcriptase drugs, as well as the correspondent resistance profiles selected during therapy. A major focus will be on the reciprocal influence of drug associations on their own metabolism as well as on the interacting effects of the selected combinations of drug resistance mutations.

PMID:: 11876577; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Supplemental Content

Related citations

Review Targeting HIV: antiretroviral therapy and development of drug resistance. [Trends Pharmacol Sci. 2002]
Review Targeting HIV: antiretroviral therapy and development of drug resistance.
Menéndez-Arias L. Trends Pharmacol Sci. 2002 Aug; 23(8):381-8.
Review HIV-1 reverse transcriptase inhibitors: current issues and future perspectives. [Curr Drug Metab. 2004]
Review HIV-1 reverse transcriptase inhibitors: current issues and future perspectives.
Locatelli GA, Cancio R, Spadari S, Maga G. Curr Drug Metab. 2004 Aug; 5(4):283-90.
Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients. [AIDS. 2009]
Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients.
Wirden M, Lambert-Niclot S, Marcelin AG, Schneider L, Ait-Mohand H, Brunet C, Angleraud F, Amard S, Katlama C, Calvez V. AIDS. 2009 Jan 2; 23(1):95-9.
Review Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection. [Antivir Ther. 2005]
Review Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.
Wainberg MA, Sawyer JP, Montaner JS, Murphy RL, Kuritzkes DR, Raffi F. Antivir Ther. 2005; 10(1):13-28.
Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies. [J Virol. 2005]
Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
Chen R, Yokoyama M, Sato H, Reilly C, Mansky LM. J Virol. 2005 Sep; 79(18):12045-57.

See reviews... See all...

Cited by 4 PubMed Central articles

Fluorinated Nucleosides: Synthesis and Biological Implication. [J Fluor Chem. 2008]
Fluorinated Nucleosides: Synthesis and Biological Implication.
Liu P, Sharon A, Chu CK. J Fluor Chem. 2008 Sep; 129(9):743-766.
High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme. [Antimicrob Agents Chemother. 2005]
High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme.
Cancio R, Silvestri R, Ragno R, Artico M, De Martino G, La Regina G, Crespan E, Zanoli S, Hübscher U, Spadari S, et al. Antimicrob Agents Chemother. 2005 Nov; 49(11):4546-54.
Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz. [Antimicrob Agents Chemother. 2005]
Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
Crespan E, Locatelli GA, Cancio R, Hübscher U, Spadari S, Maga G. Antimicrob Agents Chemother. 2005 Jan; 49(1):342-9.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Combinations against combinations: associations of anti-HIV 1 reverse transcript...
Combinations against combinations: associations of anti-HIV 1 reverse transcriptase drugs challenged by constellations of drug resistance mutations.
Curr Drug Metab. 2002 Feb ;3(1):73-95.

PubMed
Microcolumn separation of amine metabolites in the fruit fly.
Microcolumn separation of amine metabolites in the fruit fly.
Anal Chem. 2005 Aug 15 ;77(16):5349-55.

PubMed
Enhancing hypertension awareness and management in the elderly: lessons learned ...
Enhancing hypertension awareness and management in the elderly: lessons learned from the Airdrie Community Hypertension Awareness and Management Program (A-CHAMP).
Can J Cardiol. 2008 Jul ;24(7):561-7.

PubMed
Seroprevalence of vaccine preventable and blood transmissible viral infections (...
Seroprevalence of vaccine preventable and blood transmissible viral infections (measles, mumps, rubella, polio, HBV, HCV and HIV) in medical students.
Med Microbiol Immunol. 2007 Sep ;196(3):145-50. Epub 2007 Feb 2 .

PubMed
The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 p...
The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
Cancer Res. 2003 Nov 15 ;63(22):7777-84.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: